TG Therapeutics Inc. shares rose 3.7% in morning trade Monday after the company said a late-stage clinical trial for its TG-1101 with AbbVie and Johnson & Johnson's Imbruvica had positive results. The drug combination was tested in patients with previously-treated high risk Chronic Lymphocytic Leukemia, with 126 patients enrolled in the phase 3 trial. The combination showed a statistically significant improvement in overall response rate, the trial's primary endpoint, the company said. TG Therapeutics said it intends to pursue accelerated approval when it shares the results with the Food and Drug Administration later this year. TG Therapeutics shares have risen 168.2% over the last three months to $14.37, compared with a 2.2% rise in the S&P 500 .
Copyright © 2017 MarketWatch, Inc.